Table 2

p53 antibodies for immunohistochemistry

AntibodyReference (I) or contact person and year of analysis (II)DilutionCut-off to define positivity
(I) Published studies
AB-6Jankevicius et al (2002)451:10020%
BP5312Hake et al (1993)30NR10%
CM1van Ahlen et al (1997)39NR<20%, 30–80%, >80%*
DO-1Schmitz-Draeger et al (1997)381:1005%
Wolf et al (2001)441:10020%
DO-7Rödel et al (2000)411:5010%
Friedrich et al (1997)371:1005%
Leissner et al (2001)431:10020%
pAB1801Serth et al (1995)361:5020%
Kuczyk et al (1995)341:5040%
Krüger et al (2005)471:507% (observed median)
(II) Unpublished studies
DO-1US#1:Lehnert TG (1998)1:100<10%, 10–20%, >20%
DO-1 and pAB1801US#4:Adler J (1998)NRDO-1: 9%, pAB1801: 7.2% (observed medians)
US#5:Gerber M (2003)NRvarious cut-offs used; eg, 40%
unknownUS#2:Perez R (2001)NRvarious cut-offs used; eg, 25%
US#3:Kunkel A (1996)NR<20%, 20–80%, >80%
  • *Presumably printing mistake in source publication.

  • NR: not reported.